OKYO Pharma Ltd ADR (OKYO) - Net Assets

Latest as of June 2026: $12.34 Million USD

Based on the latest financial reports, OKYO Pharma Ltd ADR (OKYO) has net assets worth $12.34 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.98 Million) and total liabilities ($8.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OKYO Pharma Ltd ADR (OKYO) strategic asset index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$12.34 Million
% of Total Assets	58.81%
Annual Growth Rate	-4.35%
5-Year Change	318.51%
10-Year Change	-55.14%
Growth Volatility	79.95

OKYO Pharma Ltd ADR - Net Assets Trend (2008–2026)

This chart illustrates how OKYO Pharma Ltd ADR's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see OKYO Pharma Ltd ADR market capitalisation.

Annual Net Assets for OKYO Pharma Ltd ADR (2008–2026)

The table below shows the annual net assets of OKYO Pharma Ltd ADR from 2008 to 2026. Also explore OKYO year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2026-03-31	$12.34 Million	+322.27%
2025-03-31	$-5.55 Million	+5.61%
2024-03-31	$-5.88 Million	-186.36%
2023-03-31	$-2.05 Million	-169.66%
2022-03-31	$2.95 Million	-44.59%
2021-03-31	$5.32 Million	+3905.04%
2020-03-31	$-139.80K	-141.96%
2019-03-31	$333.14K	-82.62%
2018-03-31	$1.92 Million	-93.03%
2017-03-31	$27.50 Million	-14.08%
2016-03-31	$32.00 Million	-5.59%
2015-03-31	$33.90 Million	-27.82%
2014-03-31	$46.96 Million	+4.32%
2013-03-31	$45.02 Million	+8.83%
2012-03-31	$41.36 Million	+158.33%
2011-03-31	$16.01 Million	-70.38%
2010-03-31	$54.05 Million	+41.57%
2009-03-31	$38.18 Million	+39.06%
2008-03-31	$27.46 Million	--

Equity Component Analysis

This analysis shows how different components contribute to OKYO Pharma Ltd ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 14899700854.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Common Stock	$173.56 Million	1407.03%
Other Comprehensive Income	$-12.13 Million	-98.33%
Other Components	$2.88 Million	23.33%
Total Equity	$12.34 Million	100.00%

OKYO Pharma Ltd ADR Competitors by Market Cap

The table below lists competitors of OKYO Pharma Ltd ADR ranked by their market capitalization.

Company	Market Cap
Sahamit Machinery Public Company Limited BK:SMIT	$59.80 Million
MGI Digital PA:ALMDG	$59.83 Million
Cactus Acquisition Corp 1 Ltd NASDAQ:CCTS	$59.83 Million
Solidion Technology Inc. NASDAQ:STI	$59.84 Million
Ginar Technology Co Ltd TWO:6151	$59.80 Million
Sentry Select Primary Metals Corp TO:PME	$59.78 Million
Heron Therapeuti NASDAQ:HRTX	$59.76 Million
Ahoku Electronic Co TW:3002	$59.75 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in OKYO Pharma Ltd ADR's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from -5,549,829 to 12,335,139, a change of 17,884,968.
Net loss of 8,949,657 reduced equity.
New share issuances of 25,023,336 increased equity.
Other comprehensive income decreased equity by 2,887,702.
Other factors increased equity by 4,698,991.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	$-8.95 Million	-72.55%
Share Issuances	$25.02 Million	+202.86%
Other Comprehensive Income	$-2.89 Million	-23.41%
Other Changes	$4.70 Million	+38.09%
Total Change	$-	%

Book Value vs Market Value Analysis

This analysis compares OKYO Pharma Ltd ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.82x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 3.22x to 4.82x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2008-03-31	$0.49	$1.59	x
2009-03-31	$1.27	$1.59	x
2010-03-31	$12.62	$1.59	x
2011-03-31	$3.74	$1.59	x
2012-03-31	$9.65	$1.59	x
2013-03-31	$10.16	$1.59	x
2014-03-31	$10.14	$1.59	x
2015-03-31	$5.41	$1.59	x
2016-03-31	$5.46	$1.59	x
2017-03-31	$4.69	$1.59	x
2018-03-31	$0.33	$1.59	x
2019-03-31	$0.04	$1.59	x
2020-03-31	$-0.02	$1.59	x
2021-03-31	$0.51	$1.59	x
2022-03-31	$0.20	$1.59	x
2023-03-31	$-0.09	$1.59	x
2024-03-31	$-0.20	$1.59	x
2025-03-31	$-0.14	$1.59	x
2026-03-31	$0.33	$1.59	x

Capital Efficiency Dashboard

This dashboard shows how efficiently OKYO Pharma Ltd ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -72.55%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.70x
Recent ROE (-72.55%) is above the historical average (-173.97%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2008	-10.83%	0.00%	0.00x	1.01x	$-5.72 Million
2009	37.54%	0.00%	0.00x	1.00x	$10.52 Million
2010	23.44%	0.00%	0.00x	1.00x	$7.27 Million
2011	-10.10%	0.00%	0.00x	1.00x	$-3.22 Million
2012	-11.62%	0.00%	0.00x	1.02x	$-8.94 Million
2013	-10.75%	0.00%	0.00x	1.00x	$-9.34 Million
2014	-29.70%	0.00%	0.00x	1.01x	$-18.64 Million
2015	-24.35%	0.00%	0.00x	1.00x	$-11.64 Million
2016	-2.56%	0.00%	0.00x	1.01x	$-4.02 Million
2017	-0.88%	0.00%	0.00x	1.01x	$-2.99 Million
2018	-1476.35%	0.00%	0.00x	1.05x	$-28.49 Million
2019	-1469.36%	0.00%	0.00x	2.28x	$-4.93 Million
2020	0.00%	0.00%	0.00x	0.00x	$-1.53 Million
2021	-63.05%	0.00%	0.00x	1.33x	$-3.89 Million
2022	-184.26%	0.00%	0.00x	1.46x	$-5.73 Million
2023	0.00%	0.00%	0.00x	0.00x	$-13.07 Million
2024	0.00%	0.00%	0.00x	0.00x	$-16.24 Million
2025	0.00%	0.00%	0.00x	0.00x	$-4.15 Million
2026	-72.55%	0.00%	0.00x	1.70x	$-10.18 Million

Industry Comparison

This section compares OKYO Pharma Ltd ADR's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $249,490,347
Average return on equity (ROE) among peers: -108.27%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
OKYO Pharma Ltd ADR (OKYO)	$12.34 Million	-10.83%	0.70x	$59.80 Million
Aardvark Therapeutics, Inc. Common Stock (AARD)	$-54.64 Million	0.00%	0.00x	$120.41 Million
Abcellera Biologics Inc (ABCL)	$1.06 Billion	-15.42%	0.29x	$2.99 Billion
Abeona Therapeutics Inc (ABEO)	$1.80 Million	-188.89%	0.33x	$307.08 Million
Acumen Pharmaceuticals Inc (ABOS)	$-18.59 Million	0.00%	0.00x	$155.29 Million
Abpro Holdings, Inc. (ABP)	$-22.46 Million	0.00%	0.00x	$2.00 Million
Absci Corp (ABSI)	$176.18 Million	-62.76%	0.23x	$1.57 Billion
Arbutus Biopharma Corp (ABUS)	$101.97 Million	-62.52%	0.34x	$906.70 Million
ABVC Biopharma Inc (ABVC)	$1.25 Million	-621.32%	5.21x	$28.25 Million
Abivax SA American Depositary Shares (ABVX)	$25.93 Million	-163.70%	3.21x	$9.34 Billion
ACADIA Pharmaceuticals Inc (ACAD)	$1.23 Billion	31.86%	0.27x	$4.73 Billion

About OKYO Pharma Ltd ADR

NASDAQ:OKYO USA Biotechnology

Market Cap

$59.80 Million

Market Cap Rank

#21320 Global

#4797 in USA

Share Price

$1.59

Change (1 day)

-1.85%

52-Week Range

$1.34 - $3.27

All Time High

$3.74